{"links":{"html":"https://www.erudio.com/reports/talentop-nct04649489","json":"https://www.erudio.com/reports/talentop-nct04649489.json","markdown":"https://www.erudio.com/reports/talentop-nct04649489.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"talentop-04649489"}},"request":"https://www.erudio.com/contact?report=talentop-04649489"},"offer":{"cited_commentary_sources":35,"verified_hcp_statements":112,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":16,"optional":true,"price_per_verified_person_usd":15,"price_usd":240,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"talentop-nct04649489"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=talentop-04649489","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/talentop-nct04649489","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T13:04:54.061501Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":0},"aspects":[{"claim_count":23,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":18,"title":"Primary endpoint: TTF"},{"claim_count":14,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":11,"title":"Secondary endpoints"},{"claim_count":19,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":18,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":18,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":12,"title":"Safety and tolerability"},{"claim_count":18,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":8,"title":"Design and conduct"},{"claim_count":24,"coverage":"discussed","id":"A1","source_count":12,"title":"Response-adapted multidisciplinary implementation"},{"claim_count":10,"coverage":"discussed","id":"A2","source_count":2,"title":"Patient preference, quality of life and treatment cessation"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":8,"title":"Global adoption and reproducible resectability"},{"claim_count":13,"coverage":"discussed","id":"A4","source_count":2,"title":"Incremental patient benefit and future evidence"},{"claim_count":9,"coverage":"discussed","id":"A5","source_count":6,"title":"Integrated modalities, alternative regimens and speculative combinations"}],"counts":{"cited_sources":37,"claims_by_expression_type":{"comparison":7,"experience":7,"interpretation":35,"opinion":28,"primary_context":5,"question":4,"restatement":20,"uncertainty":2,"unspecified":4},"claims_by_kind":{"objective_result":2,"protocol_statement":3,"source_observation":107},"clinician_statements":17,"evidence_units":76,"findings":7,"organisational_accounts":4,"people_cited":21,"people_identity_verified":16,"people_total":22,"screened_sources":62,"verified_claims":112},"findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":12},"has_counterview":true,"limitations":2,"links":{"context":1,"support":15},"ma_question":true,"named_voices":6,"passages":13,"sources":7,"sources_by_kind":{"commentary":4,"media":2,"publication":1}},"title":"Practice-change enthusiasm does not establish an overall-survival benefit"},{"id":"F2","structure":{"claims":19,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":5,"views":12},"has_counterview":true,"limitations":3,"links":{"context":2,"support":21},"ma_question":true,"named_voices":11,"passages":16,"sources":12,"sources_by_kind":{"commentary":8,"media":3,"publication":1}},"title":"Upfront surgical harm is central, and safety descriptions are not interchangeable"},{"id":"F3","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":5,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":24},"ma_question":true,"named_voices":9,"passages":17,"sources":11,"sources_by_kind":{"commentary":7,"media":3,"publication":1}},"title":"Two selection gates—and disagreement about stable disease—limit applicability"},{"id":"F4","structure":{"claims":30,"claims_by_group":{"comparisons":0,"experience":3,"questions":1,"restated":3,"views":23},"has_counterview":true,"limitations":3,"links":{"context":2,"support":35},"ma_question":true,"named_voices":10,"passages":21,"sources":13,"sources_by_kind":{"commentary":9,"media":3,"publication":1}},"title":"Response should prompt multidisciplinary reassessment, not automatic continuation"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":3,"questions":1,"restated":1,"views":1},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":0,"passages":7,"sources":1,"sources_by_kind":{"media":1}},"title":"Well-tolerated systemic treatment can weaken the patient’s reason to choose surgery"},{"id":"F6","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":4,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":14},"ma_question":true,"named_voices":3,"passages":9,"sources":2,"sources_by_kind":{"media":2}},"title":"Does conversion surgery add patient benefit over continued systemic treatment?"},{"id":"F7","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":1,"questions":0,"restated":1,"views":6},"has_counterview":false,"limitations":4,"links":{"context":2,"support":10},"ma_question":true,"named_voices":5,"passages":7,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Integrated-treatment enthusiasm includes alternatives and speculative cross-study comparisons"}],"medical_affairs_question":"Which responding patients have sufficient expected incremental benefit to justify surgery, and what evidence would make that discussion credible across settings?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Practice-change enthusiasm does not establish an overall-survival benefit"},{"id":"section-2","level":2,"title":"Upfront surgical harm is central, and safety descriptions are not interchangeable"},{"id":"section-3","level":2,"title":"Two selection gates—and disagreement about stable disease—limit applicability"},{"id":"section-4","level":2,"title":"Response should prompt multidisciplinary reassessment, not automatic continuation"},{"id":"section-5","level":2,"title":"Well-tolerated systemic treatment can weaken the patient’s reason to choose surgery"},{"id":"section-6","level":2,"title":"Can conversion surgery prolong survival or improve quality of life after systemic response?"},{"id":"section-7","level":2,"title":"Integrated-treatment enthusiasm includes alternatives and speculative cross-study comparisons"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":8},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T1","label":"Primary endpoint: TTF"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":16},{"id":"F4","shared_claims":3}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F7","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":17},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":5}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T13:04:54.061501Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T13:16:09Z","record_hash":"af1b8ab288315ec186bd665b5a1d38c30c45de2c44d589df899e406dd636c272","release_hash":"f864b4739ada7f5d4b809918d0c2e7c4d45230724dcd82d3c91a031168fa31d5","report_id":"erudio-nct04649489","run_id":"4f5c7856-5e9f-4842-8776-4b94edf0651d","schema_version":"5.0","slug":"talentop-04649489","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"TALENTOP asks whether adding liver resection, followed by atezolizumab–bevacizumab, improves outcomes over continued systemic treatment after initial disease control in liver-confined HCC with macrovascular invasion. Commentary comes from X, LinkedIn and Bluesky posts, podcasts and YouTube presentations. The discussion turns on whether conversion surgery warrants a practice change while overall survival remains unresolved, whether stable disease is sufficient for surgical selection—a point of disagreement—and whether resection adds patient-centered benefit over maintenance.","meta_description":"62 sources screened · 112 verified statements (17 from clinicians verified by NPI or staff page) from 37 sources · 7 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-07afdea73c1436390837","claim-cec02cfc6bc6eabc70fa"],"id":"F3","paraphrase":"A LinkedIn post addresses who qualifies for TALENTOP after atezolizumab–bevacizumab and how to assess applicability across HCC populations.","publication_caveats":{"reason":"Source-specific publication caveats are not stated.","status":"not_set"},"source_channel":"linkedin_post","source_date":"2026-08-21","title":"Two selection gates—and disagreement about stable disease—limit applicability"},{"cited_claim_ids":["claim-2e689a1605dc62a09245"],"id":"F6","paraphrase":"A YouTube presentation asks whether resection after a systemic treatment response adds survival or quality-of-life benefit compared with continuing medication.","publication_caveats":["Who voiced this question is not established in the sources reviewed for this edition.","This historical treatment discussion does not report comparative TALENTOP outcomes."],"source_channel":"youtube","source_date":"2021-10-23","title":"Does conversion surgery add patient benefit over continued systemic treatment?"}]},"publication":{"approved_at":"2026-10-31T13:16:09Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":62},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on continued systemic treatment burdens when conversion surgery is not indicated or tolerated.","Not yet captured in this edition: a view on conversion-treatment alternatives to resection, followed by consolidation and possible treatment cessation.","Not yet captured in this edition: a view on short follow-up, tentative recurrence-free survival extrapolation, and randomized confirmation of benefit from conversion surgery.","Not yet captured in this edition: a view on postoperative recurrence-free survival versus response duration as a proposed benchmark for surgery or continued systemic treatment.","Not yet captured in this edition: a view on benefits and risks of conversion surgery versus maintenance therapy for hepatocellular carcinoma with vascular invasion.","Not yet captured in this edition: a view on whether increasingly tolerable systemic treatment limits the additional quality-of-life benefit of conversion resection.","Not yet captured in this edition: a view on the safety trade-offs of conversion surgery versus maintenance systemic therapy after initial treatment.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","30 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","This report describes the sources reviewed for this edition, not all HCP discussion or a representative sample of clinical opinion.","Parts of the early conversion-treatment discussion remain incompletely represented, including treatment-stopping burdens, nonoperative local options and comparisons of benefit duration.","Repeated posts, reposts, relayed presentations and organizational accounts cannot be treated as independent clinician endorsements or used to estimate consensus.","The identity of speakers in the 2021 conversion-treatment presentation and the POST ESMO 2025 episode is not established for the statements used here.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Differences in endpoint labels, safety percentages, denominators and emphatic survival interpretations remain attributed to their authors rather than reconciled into a single clinical result.","Historical patient experiences and preliminary conversion-treatment observations are not TALENTOP comparative outcomes.","No separate protocol document or exact combination-product label was available; the registry and published results provide the primary study context."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":2,"other":0,"podcast":2,"publication":1,"registry":1,"regulatory":0,"x_thread":25,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":35,"methods":1,"results":1},"count":37,"evidence_window":{"end":"2026-10-10","start":"2021-10-23"},"retrieval_snapshot":"2026-10-31T12:17:52.805807Z","timeline":[{"count":1,"week":"2021-W42"},{"count":13,"week":"2025-W43"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W48"},{"count":1,"week":"2026-W23"},{"count":8,"week":"2026-W34"},{"count":4,"week":"2026-W35"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04649489:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04649489:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41057233","quote_policy":"short_quote_link_out"},{"id":"pubmed:42624156","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3m3m7xvnb3c22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3m3mafalta222","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47nm5qperrpmcqdmzxt3qgec-3mtlirfhybc2c","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7496542481073827841","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7497204688837128193","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7499768872183635970","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:196e47","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:73f9c6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:efc0d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1337026905388748801:9a549613-3b50-464e-a491-fc930d045e48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971859493060252134:c0bb1be1-df49-46cd-bbbd-e5efb97ab208","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979938500100190676:adffd318-7bf8-4a21-b864-6ffe32e1adc9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980140769357754621:c92c6043-b8c3-4c6b-9a70-62de5e2a6cb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980164183728484862:265ecbcf-781e-4b2e-bcb2-21481927faf5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980165996519583842:e2173ce3-0b69-4d10-8e86-6da2f2977e0d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980166368604328219:2566a993-0963-49df-981e-fcfc8e351f1f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980168503601803372:b00d2238-a912-421d-aa0b-44e3a8edfe8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980200970685481008:aa943e2a-5b36-44d8-b906-cc398a3c49fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980258670517584381:8e1d6048-2734-401f-9fc1-3f9d87d7b7de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980278421319016577:af925565-b6ed-4bd6-9270-6b43554ee4ac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980343659389386928:0d5df5b9-9b65-40de-9d01-09d0b5acdfac","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980357885772337631:4b32a1e1-ecd1-48a5-999d-645d753e1f65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980541087363265022:2daed834-ab08-4733-97eb-0d211cfa8ee9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980695216144412728:1148c817-0125-4dac-9178-e8c406c606a0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980707061253255323:17999e7d-3a47-4705-bd29-249d5198f321","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993484853296210108:55bde2d4-f09e-48c4-82ec-e9c334904de6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1993566444332961983:68c51288-b58a-450d-8354-e987cd5954b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018841370056667369:51bd04d7-c8af-4b86-93fd-4efcc4d0bf50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2019101017900810702:7aaaeef7-bb5c-4f60-8905-aa2e4ab99f58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061421045341462865:3755db96-1e6b-4d03-b5ca-f75866555659","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090740407856476168:d7183f5f-6dc1-44ed-85a6-0c09cbd7a46d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090740922590064670:c63d6492-3ac5-45ef-8464-6b2e5dffd8fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090758903155823077:b86d1f13-16d1-43d3-b8c2-36fa7af57ebf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090776706957099254:5b51ef6a-7af2-4acb-a664-d51c98ce0781","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090831650795979098:26ed0a75-b606-4b22-a279-faf71e635711","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090838925111611546:72a2589f-de85-4e86-964e-9a5268368541","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090865563731935251:3c79384b-991e-4441-8e6e-9494204129ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090917162127139071:b1565138-ae1c-45a5-9fe9-1a8eefbafc9f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091201429658575139:dedc961f-66e5-4a00-94e7-0c1476915328","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091377655044362539:e8af1eff-c666-4640-a326-47126efb2f8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091818411743425019:810bb1cd-8c83-4a0b-8bf8-6670782efbca","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091819094924484644:61579eda-13fb-43ee-a264-90e096dd9b6d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091928086904230153:5ecdd808-0340-45c5-b303-acfe1a36c144","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092223909667992051:69be52d0-d535-4457-96bb-eca826bae05c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092302636725014548:234521f3-a056-4b4a-8fba-84ea59a45c39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2092854825184878718:2860d6dc-4902-4330-adbf-f7acfb116a43","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2093985672424300732:c6faf814-ea5a-4c3f-9cdd-fc2e9e4d7725","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094732534026547488:ac3b5728-2217-4375-a330-a6e81cc12793","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095146709944795290:59b58a62-1d58-4607-b1be-7d00a3bac2ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095480700669472778:36480f38-a067-4219-9b4f-63f78fe7b067","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095501272778494188:2a47df6c-15a3-45ab-ab71-79af15545f5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095508694444249301:db2bbe17-04d8-41c0-9572-6dcdc1bb7871","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096222038981578755:2d3c1d12-4834-4ab6-933a-8c38b6a04168","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096280697057218595:b9efb5c9-4f80-4f44-8071-f03f47649522","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2096959164975136893:c4603e3e-2141-40d9-a03e-8da5b0c0faa1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097902955429322806:d94e2bf4-9b1e-4e81-ab86-e435a51b25e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100692268923699403:3528fe98-2e54-40a1-b785-c8e0e5aeb50b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108920597736796463:212e5dbe-7f9a-491f-a1d7-daf1a4bb556a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:AabfzDVzle4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:M4Dvm87jO1g","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:XC2AF47UUf8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:yDkjMvn0DSc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":3,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":49,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":62},"count":62,"evidence_window":{"end":"2026-10-10","start":"2020-12-10"},"retrieval_snapshot":"2026-10-31T12:17:52.805807Z","timeline":[{"count":1,"week":"2020-W50"},{"count":1,"week":"2021-W42"},{"count":1,"week":"2025-W39"},{"count":1,"week":"2025-W42"},{"count":16,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W46"},{"count":3,"week":"2025-W48"},{"count":2,"week":"2026-W06"},{"count":1,"week":"2026-W23"},{"count":13,"week":"2026-W34"},{"count":9,"week":"2026-W35"},{"count":7,"week":"2026-W36"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: atezolizumab & bevacizumab","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Venous Thrombosis","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"TALENTOP","aliases":["TALENTOP","A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment"],"brief_title":"A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Venous Thrombosis"],"enrollment":{"count":501,"type":"ESTIMATED"},"interventions":[{"name":"Atezolizumab & Bevacizumab","synonyms":["Bevacizumab"],"type":"DRUG"},{"name":"Surgery followed by atezolizumab and bevacizumab","synonyms":["Atezolizumab","Bevacizumab"],"type":"PROCEDURE"}],"nct_id":"NCT04649489","official_title":"A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-08-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Time-to-treatment failure (TTF) after randomization, defined as the time from randomization to the first documented treatment failure (i.e., local recurrence or progression, EHS, or death from any cause). Tumor response will be determined by the IRF according to RECIST v1.1","measure":"TTF","timeFrame":"24 months"}],"registered_date":{"date":"2020-12-02","type":"ACTUAL"},"registry_last_updated":"2026-01-15","registry_url":"https://clinicaltrials.gov/study/NCT04649489","short_name":"TALENTOP","short_name_basis":"registry_acronym","sponsor":"Jia Fan","start_date":{"date":"2021-04-19","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"ML42435","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}